Neutralization of Hepatitis C Virus (HCV)


Available for licensing and commercial development are compositions and methods for preventing and/or treating infection caused by hepatitis C virus (HCV). The invention is based on mapping studies conducted by the inventors of two epitopes within HCV E2: epitope I and epitope II. It has been discovered that epitope I is involved in virus neutralization but that epitope II mediates antibody interference, probably an adaptation of the virus to obfuscate the immune system. In an effort to attenuate or disable the interference effect of HCV-E2 epitope II, the present invention is directed to a HCV E2 polypeptide substitution/deletion of native amino acids LFY in epitope II, a HCV E2 polypeptide insertion of amino acids between the native LFY in epitope II, or the use of epitope II as a molecular decoyant or to affinity-purify an immune globulin to deplete interfering antibodies from, and enrich neutralizing antibodies in, the preparation.

Potential Commercial Applications: Competitive Advantages:
  • HCV vaccines
  • HCV therapeutics
 Improved HCV vaccines and therapeutics


Development Stage:
The technology is currently in the preclinical stage of development.

Inventors:

Pei Zhang (FDA)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 8,603,468 issued 2013-12-10
US Application No. 12/741,612

Publications:
P Zhang et al. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci USA. 2007 May 15;104(20):8449-8454. PubMed abs
MY Yu et al. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci USA. 2004 May 18;101(20):7705-7710. PubMed abs

Collaboration Opportunity:

The FDA Center for Biologics Evaluation and Research, Laboratory of Plasma Derivatives, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Alice Welch, Ph.D. at 301-827-0359 or Alice.Welch@fda.hhs.gov for more information.


Licensing Contact:
William Ronnenberg, M.S., J.D.
Email: william.ronnenberg@fda.hhs.gov
Phone: 240-402-4561

OTT Reference No: E-276-2007-1
Updated: Oct 7, 2009